Phase 4
N=34
Study of SOC Plus IVIG Compared to SOC Alone in the Treatment of COVID-19
Sars-CoV2
Bottom Line
View on ClinicalTrials.gov: NCT04411667 ↗Enrolled (actual)
34
Serious AEs
0.0%
Results posted
Jun 2021
Primary outcome: Primary: Mechanical Ventilation — 2; 7 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Octagam (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- George Sakoulas, MD
- Primary completion
- Jun 2020
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mechanical Ventilation |
2; 7 | — |
| SECONDARY Oxygen Therapy |
— | — |
| SECONDARY Length of Stay |
12; 17 | — |
Summary
The purpose of this research is to see if Intravenous Immunoglobulin (IVIG) can help reduce respiratory complications (respiratory failure and need for a ventilator) caused by coronavirus disease 2019 (COVID-19). The principal investigator has successfully utilized IVIG for patients infected with the influenza virus. The investigator wants to find out if IVIG is equally effective in COVID-19 infection patients, and if IVIG will give the immune system some help to clear the infection naturally.
Eligibility Criteria
Inclusion Criteria
- Confirmed COVID-19 positive test result (including presumptive positive).
- Hospitalization
- Requiring ≥4 liters/min O2 nasal cannula to maintain oxygen saturation ≥ 92%, but not mechanically ventilated
- Age ≥18 years old.
- Access to a phone in the hospital room or an electronic device that is capable of receiving phone calls and/or video calls and/or e-mail.
- Able to read/write/speak English or Spanish fluently.
- Subjects must have the capacity to provide consent or an appropriate Legally Authorized Representative (LAR) to provide informed consent.
provide informed consent, and provide authorization of use and disclosure of personal health information.
- Negative pregnancy test for women of childbearing potential.
Exclusion Criteria
- Severe allergy to any IVIG product formulation
- History of DVT, PE, thromboembolic stroke or other thrombotic events
- Hypersensitivity to corn. Octagam® contains maltose which is a sugar derived from corn.
- Uncontrolled hypertension (SBP>180 mm Hg or DBP>120mmHg)
- Active participant in another research treatment study
- Mechanically ventilated patient
- Code status is Do Not Resuscitate or Do Not Intubate
Data sourced from ClinicalTrials.gov (NCT04411667). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.